9 Newly Approved Novel Drugs
9 Newly Approved Novel DrugsIt's still early in 2017, but the FDA has been approving drugs left and right. Here's what you need to know.
Constipation drug wins approvalFDA approved plecanatide (Trulance, Synergy Pharmaceuticals) for adults with chronic idiopathic constipation.
Wet pants and constipationThe relationship between the urinary tract and the lower gastrointestinal tract impacts urinary tract infections (UTIs) and urinary incontinence in children.
Optimizing care for children with constipationThere is no question that pediatricians are experienced in managing constipation considering its prevalence among children. Research shows, however, that the majority of pediatricians are not aware of recently released evidence-based recommendations for both the diagnostic evaluation of children with constipation and the treatment of functional constipation, said Samuel Nurko, MD, MPH, associate professor of pediatrics, Harvard Medical School, Boston, Massachusetts.
Synergy Pharmaceutical's constipation drug garners positive resultsSynergy Pharmaceuticals’ drug for chronic idiopathic constipation (CIC) has garnered very positive results in a phase 3 clinical trial, the company reported this week.
Study to examine laxative use in childrenThe US Food and Drug Administration has awarded a research grant to the Children’s Hospital of Philadelphia to study the safety of an adult laxative commonly used in children.
FDA approves subcutaneous injection for opioid-induced constipation in chronic non-cancer painFDA approved methylnaltrexone bromide (Relistor, Salix Pharmaceuticals and Progenics Pharmaceuticals) subcutaneous injection, 12 mg/0.6 mL, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain.
FDA warning: OTC sodium phosphate overdose can be deadlyOver-the-counter sodium phosphate drugs can cause serious injury to kidneys and the heart if more than 1 dose is taken in 24 hours, according to an FDA warning.
FDA Drug ApprovalsPipeline preview, FDA actions in brief
Linzess (Linaclotide)New molecular entity: FDA approved linaclotide (Linzess, Ironwood Pharmaceuticals and Forest Pharmaceuticals) for the treatment of chronic idiopathic constipation and irritable bowel syndrome (IBS) with constipation in adults.